NCT03600701 is a phase II trial assessing the effect of atezolizumab (anti-PD-L1 antibody) and cobimetinib (MEK inhibitor) for the treatment of patients with metastatic, recurrent, or refractory NSCLC [38]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.